We are live on ! Find out more
NTLA icon

Intellia Therapeutics
NTLA

284 hedge funds and large institutions have $2.53B invested in Intellia Therapeutics in 2023 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 120 increasing their positions, 66 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more repeat investments, than reductions

Existing positions increased: 120 | Existing positions reduced: 66

1.75% more ownership

Funds ownership: 88.8% → 90.55% (+1.8%)

4% more call options, than puts

Call options by funds: $13.4M | Put options by funds: $12.8M

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

8% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 37

2% less funds holding

Funds holding: 290 → 284 (-6)

21% less capital invested

Capital invested by funds: $3.19B → $2.53B (-$656M)

Holders
284
Holders Change
-6
Holders Change %
-2.07%
% of All Funds
4.51%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
34
Increased
120
Reduced
66
Closed
37
Calls
$13.4M
Puts
$12.8M
Net Calls
+$567K
Net Calls Change
+$17M

Top Buyers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
+$45.2M
2
AIM
ARK Investment Management
Florida
+$16.4M
3
TCM
Tang Capital Management
California
+$15.4M
4
Citadel Advisors
Citadel Advisors
Florida
+$14.2M
5
Morgan Stanley
Morgan Stanley
New York
+$9.38M

Top Sellers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
-$10.5M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$9.64M
3
IHAM
Integral Health Asset Management
New York
-$8.4M
4
Goldman Sachs
Goldman Sachs
New York
-$8.05M
5
Nomura Holdings
Nomura Holdings
Japan
-$7.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
101
Profund Advisors
Maryland
$1.28M +$178K +4,592 +13%
Janus Henderson Group
102
Janus Henderson Group
United Kingdom
$1.2M +$78 +2 +0%
PP
103
PDT Partners
New York
$1.17M +$1.44M +37,077 New
Envestnet Asset Management
104
Envestnet Asset Management
Illinois
$1.16M +$679K +17,500 +91%
SIA
105
Sit Investment Associates
Minnesota
$1.09M – – –
Ameriprise
106
Ameriprise
Minnesota
$1.05M +$644K +16,602 +99%
First Trust Advisors
107
First Trust Advisors
Illinois
$1.05M +$1.29M +33,208 New
RJFSA
108
Raymond James Financial Services Advisors
Florida
$1.01M +$216K +5,574 +21%
ECM
109
ExodusPoint Capital Management
New York
$994K +$938K +24,178 +333%
RCA
110
Resonant Capital Advisors
Wisconsin
$989K +$1.21M +31,266 New
Ensign Peak Advisors
111
Ensign Peak Advisors
Utah
$969K – – –
Commonwealth Equity Services
112
Commonwealth Equity Services
Massachusetts
$962K +$74.1K +1,910 +7%
LP
113
LMR Partners
United Kingdom
$958K +$450K +11,600 +62%
CRC
114
Curi RMB Capital
Illinois
$887K +$159K +4,103 +17%
Victory Capital Management
115
Victory Capital Management
Texas
$864K +$18.2K +470 +2%
WM
116
WS Management
Florida
$843K – – –
HighTower Advisors
117
HighTower Advisors
Illinois
$808K -$91.6K -2,360 -8%
State Board of Administration of Florida Retirement System
118
State Board of Administration of Florida Retirement System
Florida
$796K +$5.04K +130 +0.5%
SAM
119
Shell Asset Management
Netherlands
$772K -$2.13K -55 -0.2%
Osaic Holdings
120
Osaic Holdings
Arizona
$759K +$154K +3,978 +20%
IBT
121
International Biotechnology Trust
United Kingdom
$758K – – –
Principal Financial Group
122
Principal Financial Group
Iowa
$758K +$133K +3,440 +17%
CSS
123
Cubist Systematic Strategies
Connecticut
$754K +$925K +23,836 New
Canada Life
124
Canada Life
Manitoba, Canada
$747K +$217K +5,592 +31%
EGM
125
Engineers Gate Manager
New York
$738K +$626K +16,143 +224%
3 4
5
6 7

NTLA Hedge Fund Activity: Q3 2023 in Review

284 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2023, worth a combined $2.53B — down 21% from $3.19B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of NTLA and 34 opened new positions — a net loss of 3 holders — while 66 trimmed existing stakes and 120 added.

The largest buyer was Deep Track Capital, adding an estimated $45.2M. The largest seller was Charles Schwab, cutting an estimated $10.5M.

  • 284 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2023, down from 290 in Q2 2023.
  • Funds reported $2.53B of Intellia Therapeutics stock for Q3 2023, down 21% quarter-over-quarter.
  • 34 funds opened new Intellia Therapeutics positions in Q3 2023 and 37 closed out, a net change of -3 holders.
  • The largest Intellia Therapeutics buyer in Q3 2023 was Deep Track Capital, an estimated $45.2M added.
  • The largest Intellia Therapeutics seller in Q3 2023 was Charles Schwab, an estimated $10.5M sold.

Based on aggregated 13F filings for Q3 2023.